Sunset Island Group Announces Update on Expansion and Retro Fit of Greenhouse
February 07, 2018 10:16 ET | Sunset Island Group, Inc.
SALINAS, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- SUNSET ISLAND GROUP, INC. (OTCQB:SIGO) is pleased to provide an update to its shareholders regarding the Retro Fit and Expansion...
Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
January 05, 2017 09:05 ET | Ocera Therapeutics, Inc.
Data Support Feasibility of Oral OCR-002 as Maintenance Therapy for Patients with Hepatic Encephalopathy Company Plans to Initiate Phase 2a in H1 2017 with New Optimized Tablet Formulation PALO...
Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy
September 19, 2016 09:05 ET | Ocera Therapeutics, Inc.
--Phase 2b STOP-HE Enrollment Surpasses 205 Patients; On Track to Complete in Q4 2016-- PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics,...
ContraFect Announces Fourth Quarter and Full Year 2015 Results
March 15, 2016 07:00 ET | ContraFect Corporation
YONKERS, NY--(Marketwired - March 15, 2016) -  ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
Achillion-Logo-150 (4).jpg
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
December 05, 2015 17:00 ET | Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
November 16, 2015 16:05 ET | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Rhizen Pharmaceuticals S.A. to present preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in Multiple Myeloma
November 18, 2014 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a poster presentation for RP6530, a novel dual PI3K delta/gamma inhibitor in Multiple Myeloma. ...
Semafore Pharmaceuticals to Present SF1126 Clinical Data at ASCO Annual Meeting
May 26, 2011 08:30 ET | Semafore Pharmaceuticals
INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of...